Discover 2,226 paid clinical trials in San Francisco, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
San Francisco offers opportunities for individuals interested in taking part in paid studies as healthy volunteers, as well as those looking for studies for a specific medical condition. The city has a strong emphasis on cutting-edge research for conditions such as HIV/AIDS, oncology, kidney disease, PCOS, and endometriosis, among others. By participating, you can gain access to the latest healthcare innovations and contribute to pioneering medical progress.
Filter
2
Filter results
Results: 2,226
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
for
Chronic Myelomonocytic Leukemia,
Location: Stanford CA, Portland OR, Rochester MN, Houston TX,
Sponsor: Solu Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT06950034
Phase1, Recruiting
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
for
Multiple Sclerosis (MS),
Location: San Francisco CA
Sponsor: University of California, San Francisco
Sex: All
Age: 18 - 55
Code: NCT05359653
Phase1, Phase2, Recruiting
A Study of Psychedelics in Healthy Older Adults With Low Well-being
for
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Location: San Francisco CA
Sponsor: Jennifer Mitchell
Sex: All
Age: 50 - 70+
Code: NCT07386730
Phase1, Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Location: San Francisco CA, San Antonio TX, Houston TX,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT06952010
Phase1, Recruiting
Blood Specimen Collection For Laboratory Assay Research
for
General; Metabolic Disorder, Sexual Dysfunction, Hair Loss,
Location: San Francisco CA
Sponsor: Roman Health Ventures Inc.
Sex: All
Age: 18+
Code: NCT06046651
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer